30/03/2023
Cantheon Provides Funding to Albert Labs for Psilocybin Drug Development
Canadian biopharmaceutical company Albert Labs International Corp. secured a C$830,000 ($621,600) injection from psychedelic pharmaceutical investment firm Cantheon Capital LLC.
The study is expected to cost C$2.7 million and will run for three months. The post Cantheon Provides Funding to Albert Labs for Psilocybin Drug Development...